• On 27 June 2026, Chemed Corporation (NYSE: CHE) was removed from several Russell growth and midcap benchmarks, including the Russell 1000 and 3000 Growth indexes.
• This broad index removal matters because it can trigger forced trading by index-tracking funds, potentially reshaping Chemed’s shareholder base and liquidity profile.
• Against this backdrop of Chemed’s removal from multiple Russell growth indexes, we’ll now examine how this development intersects with its existing investment narrative.

Find 43 companies with promising cash flow potential yet trading below their fair value.

Chemed Investment Narrative Recap

To own Chemed, you need to be comfortable with a story built on VITAS’s hospice scale and Roto Rooter’s cash generation, but also with heavy exposure to US government reimbursement and execution risks in both segments. The broad Russell index removals may affect trading activity and short term volatility, yet they do not directly change the core near term catalyst around stabilizing VITAS margins or the key risk tied to Medicare and Medicaid reimbursement.

Against this indexing backdrop, Chemed’s ongoing share repurchases stand out. In Q1 2026 the company bought back 500,000 shares for US$197.68 million, continuing a long running program that has retired more than 12.36 million shares in total. For investors focused on earnings per share and ownership concentration, this capital return framework sits right alongside VITAS’s operational reset as a central part of the current thesis and near term catalysts.

Yet despite those reassuring buybacks and dividends, the concentration of reimbursement risk in VITAS is something investors should be aware of if...

Chemed's narrative projects $3.1 billion revenue and $386.5 million earnings by 2029. This requires 6.6% yearly revenue growth and about a $126.7 million earnings increase from $259.8 million today.

Uncover how Chemed's forecasts yield a $446.50 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Some analysts see a much brighter path, assuming revenue could reach about US$3.1 billion and earnings US$417.5 million, but after this index exit your own view on VITAS mix and Medicare exposure may differ sharply from those optimistic forecasts.

Explore 4 other fair value estimates on Chemed - why the stock might be worth as much as 47% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Chemed research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Chemed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemed's overall financial health at a glance.

No Opportunity In Chemed?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.